Cantargia performs IPO ahead of planned listing on Nasdaq First North in Stockholm

An extraordinary general meeting of Cantargia AB ("Cantargia") on 13 January 2015 decided, in accordance with the board's proposal, to implement an IPO consisting of shares and option rights during the period January 27th – February 12th 2015. If fully subscribed, the IPO will initially bring the company approximately SEK 44.1 million through shares. Full utilisation of the associated option rights would later bring the company an additional SEK 55.1 million, approximately. The fully-subscribed issue and fully utilised option rights would bring the company approximately SEK 99.2 million before IPO expenses. Cantargia has received subscription commitments and guarantees of approximately SEK 39 million, corresponding to around 88 per cent of the initial volume.

About Cantargia AB
Cantargia AB is a biotechnology company that develops antibody-based cancer treatment, which attacks both cancer stem cells and mature cancer cells. The original discovery of the research group behind Cantargia is the expression of a specific receptor molecule, "IL1RAP", on cancer stem cells from patients with leukemia that is not found on normal bone marrow stem cells. In pre-clinical studies (in vitro and in vivo), the antibody directed towards IL1RAP has demonstrated two potential modes of action that complement each other. The company has chosen a product candidate for future studies in humans. Preclinical studies with Cantargia's antibodies have demonstrated a potent anti-leukemia effect. Parallel pre-clinical studies have shown an even higher expression of IL1RAP in certain solid tumours. During the forthcoming year, Cantargia will perform studies required to start clinical trials.

Cantargia is now implementing an IPO in advance of a planned listing.

Purpose of the issue and planned listing on First North in Stockholm
The IPO purpose is to provide the company with funds for preclinical activities as a first stage and for a subsequent focused clinical phase I/IIa trial. The planned listing on First North in Stockholm depends on Cantargia being approved in the marketplace. The listing process has been initiated.

The offer in brief
Subscription period:               
January 27th – February 12th 2015.

Subscription size:
Minimum subscription is 200 units. Each unit consists of four shares, three option rights series TO 3 and two option rights series TO 4.

Subscription price:
SEK 30.40 per unit, which corresponds to SEK 7.60 per share. The option rights are issued free of charge. There is no brokerage.

Issue volume:
The offer comprises a maximum of 5,800,000 shares, a maximum of 4,350,000 option rights series TO 3 and a maximum of 2,900,000 option rights series TO 4. The initial issue totals approximately SEK 44.1 million and full utilisation of the option rights would bring Cantargia approximately a further SEK 55.1 million before deduction of IPO expenses.

Valuation:
Approximately SEK 57.7 million (pre-money).

Option rights:
One (1) option right gives the right to subscribe to one (1) new share. The redemption period for TO 3 is March/April 2016. The redemption period for TO 4 is September/October 2016. The redemption price for each series is SEK 7.60 per option right.

Subscription commitments and guaranteed subscription
Cantargia has received subscription commitments of approximately SEK 25.6 million and guaranteed subscription of approximately SEK 13.4 million, a total of approximately SEK 39 million. This corresponds to approximately 88 per cent of the initial issue. After subscription undertakings, it will be possible for the general public to subscribe up to approximately SEK 18.5 million in the issue, corresponding to approximately 42 per cent of the initial issue. In the event that the issue is not fully subscribed, the guarantors have undertaken to subscribe to the remaining units required for a fully-subscribed issue, up to a maximum number of units corresponding to the guarantee amount of approximately SEK 13.4 million.

Financial Consultant and Certified Adviser
Sedermera Fondkommission is financial consultant and certified adviser to the company in connection with the issue and the planned listing on First North.

Investor meetings
In connection with the issue, the company's representatives will participate in a number of investor meetings, to inform about the business and the company's plans for the future. Attendance at the investor meetings is free of charge and light refreshments will be served. For further information about the investor meetings and to register, please contact Sedermera Fondkommission by e-mail: anmalan@sedermera.se or telephone: +46 (0)431 47 17 00.

  • 27.01.2015,15.00-15.30, investor meeting (Aktiespararna), Elite Hotel Ideon, Scheelevägen 27, Lund.
  • 28.01.2015,11.30-12.30, lunch meeting, Vardagsrummet, Bryggaregatan 14, Piteå.
  • 28.01.2015,17.30-18.30, investor meeting, Scandic Hotell, Vithatten, Skellefteå.
  • 29.01.2015,18.00-20.30, investor meeting, Scandic Klara, Slöjdgatan 7, Stockholm.

For questions regarding the issue, contact
Sedermera Fondkommission
Telephone: +46 (0)431 47 17 00
E-mail: info@sedermera.se

Prospectus and registration form
A prospectus containing complete conditions and directions is now available for download from the websites of the company (www.cantargia.com) and Sedermera Fondkommission (www.sedermera.se). A folder and registration form will be available via the above websites no later than when subscription opens.

For further information, contact:
Göran Forsberg, CEO
Telephone: +46 (0)46 275 6260
E-mail: goran.forsberg@cantargia.com

About Us

Cantargia AB (publ), reg.no. 556791-6019, is a biotech company which is listed on Nasdaq Stockholm First North (ticker: CANTA). Sedermera Fondkommission is the company’s Certified Adviser. More information about Cantargia is available at http://www.cantargia.com.

Subscribe

Documents & Links